Tamoxifen and allele

[EPguy]

This therapy has been discussed on the forum. A recent study says <those with high levels of STAT3 and STAT5 activation as well as possessing an inflammation signature>> respond to the drug.

onclive.com/view/tamoxifen-...

<<Of 32 patients who completed 24 weeks of tamoxifen treatment, 3 responders showed at least a 50% reduction in VAF, which was the study’s primary end point. A further 5 patients were classified as minor responders, showing reductions of at least 25% but lower than 50% in allele burden.>>

Implication is if the patients are screened for STAT3 etc the results could be quite good.

I've not had data on these STAT or inflammation sig, but this suggest at least for INF non-responders it could be worth looking into. This summary does not address toxicity.

Curious how it might work as an INF combo too.

[Rem31]

It’s interesting to see this. I’m calr type 1 and was asked in 2019 if interested in taking part in the study. I was very disappointed to then find I couldn’t be included due to a post op DVT 25+ yrs ago. IF I’ve remembered correctly, one of the reasons for my exclusion was there maybe a very small increased risk of clotting with tamoxifen.

[EPguy in reply to Rem31]

It seems that Tomoxifen is touchy stuff. It does have this limitation, likely why you were not admitted:

<<Patients were excluded if ... had a previous thrombotic event at any time>>

There's also no discussion I see of CALR results in this report.